65,437 trials
Metastatic Non-Small Cell Lung Cancer
Primary: Progression-free Survival (PFS) Among Subjects With KRAS Mutation Positive NSCLC (ITT Population) Treated With Erlotinib Plus Tivantinib Compared to Single Agent…
Poorly Differentiated Thyroid Gland Carcinoma · Recurrent Thyroid Gland Carcinoma · Stage I Thyroid Gland Follicular Carcinoma
Primary: Objective Response Rate, Defined as the Proportion of Patients Who Have Had a PR or CR as Assessed by the RECIST Version (v)1.1 — 10 Participants
Acute Myeloid Leukemia · Adult Acute Megakaryoblastic Leukemia · Adult Acute Monoblastic Leukemia
Primary: Progression-free Survival — 41.2; 26.9 percentage of patients
Influenza
Primary: Percentage of Participants With Fever (Fever Rate) Following Vaccination With Fluzone Quadrivalent Vaccine — 11.31; 12.15 percentage of participants
Candidates for Systemic Therapy for Psoriasis · Psoriasis
Primary: Percentage of Subjects With Physician's Global Assessment (PGA) Ratings of "Excellent" or "Cleared" at Week 24 — 46.0 percentage of subjects
Spinal Cord Injuries
Primary: Change in Over Ground Gait Speed as Assessed by the 10 Meter Walk Test — -6.815; -0.5 seconds
Gastric Adenocarcinoma · Gastroesophageal Adenocarcinoma · Distal Esophageal Adenocarcinoma
Primary: Number of Participants With Progression at the 3 Month Follow up Visit — 15; 7 participants
Benign Paroxysmal Positional Vertigo
Primary: Likert Scale for Satisfaction — 9; 9 units on a scale
Cognitive Function
Primary: Non-Inferiority of DCTclock Compared to Mini-Mental State Examination (MMSE) — -0.035 Difference in Quadratic Weighted Kappas
Graft Versus Host Disease · Leukemia · Lymphoma
Primary: Transplantation-related Mortality at 100 Days Post-transplantation — 2 Participants
Breast Cancer
Primary: Number of Patients Eligible Compared to the Number Approached and Enrolled — 61; 252; 30; 31 Participants
Methicillin-Resistant Staphylococcus Aureus
Primary: Proportion of Participants With MRSA Clearance — 8; 4 Participants — p=0.320
Chronic Obstructive Pulmonary Disease (COPD) · Heart Failure
Primary: Function Capability — 349; 338 meters
Behavior Problems, Child
Primary: Change in Child Behavior Problems — 67.0; 67.6; 60.4; 59.9 units on a scale
Saphenous Nerve Block
Primary: Block Success — 18; 22 participants — p=0.25